Shots:

• Roche is presenting data that includes results assessing Tecentriq + nab-paclitaxel in Breast Cancer (P-III)- Alecensa in lung cancer and Tecentriq in lung (P-III) and liver cancers(P-I)
• Additionally- presenting Entrectinib’s (RXDX-101) positive results from P-II STARTRK-2- P-I STARTRK-1 and P-I ALKA trials for NTRK gene fusion-positive solid tumors and also received BT and PRIME medicine designation from the US FDA and EMA respectively
• OS and PFS from P-III IMpower130 study will also be presented at ESMO 2018 assessing Tecentriq + CT (carboplatin and nab-paclitaxel) vs CT for advance NSCLC and PFS of P-III ALESIA study assessing Alecensa vs crizotinib for (ALK)-positive advanced NSCLC

Ref: Roche | Image: Roche